havahtx.com
Manufacturing · Colorado, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
2112 Andrew Alden St, Longmont, Colorado...Website
www.havahtx.comRevenue
$5.5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About havahtx.com
HavaH Therapeutics is focused on developing innovative androgen therapies aimed at treating breast diseases, particularly hormonal refractory ER+ breast cancer and metastatic cancer. The company utilizes a unique hormonal modulation approach to provide safer and more effective treatment options for early-stage hormone receptor positive breast cancer, specifically Ductal Carcinoma In-Situ (DCIS). With a significant clinical exposure and promising results, HavaH aims to reduce the long-term risks associated with breast cancer progression and minimize the need for invasive surgical procedures. Their advanced product, T+Ai, is designed to maintain optimal hormonal balance in breast tissue, offering a new avenue for breast cancer prevention and treatment.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is havahtx.com your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on havahtx.com recently announced quarterly report
Product Launch: Get notified when havahtx.com launches new products
Check if havahtx.com has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at havahtx.com
havahtx.com, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if havahtx.com had a recent Job posting/layoffs
Funding: Get notified immidiatlly once havahtx.com has new funding data
Website visits: Recent activity has been detected on your website
Check out if havahtx.com is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined havahtx.com as Masked Content
Find 2 more new buyers
Compare Similar Companies to havahtx.com
Compare insights from companies similar to havahtx.com, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
havahtx.com
$5.5M
1-10
Private
-
-
N/A
Company Profile Activity
Activity Insights
havahtx.com is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
havahtx.com is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about havahtx.com.
havahtx.com Tech Stack
A closer look at the technologies used by havahtx.com
havahtx.com News & Media
Havah Therapeutics Granted Additional Patent Protection for T+Ai™
BOULDER, Colo.--(BUSINESS WIRE)--Havah Therapeutics today, announced that the United States Patent and Trademark Office (USPTO) has granted a new patent (US Patent No. 12,128,055) for its innovative T+Ai combination therapy—a novel composition of testosterone and anastrozole in a long-acting, slow-release subcutaneous implant. “Our new patent for T+Ai is a critical milestone as we advance through the ongoing RECAST DCIS Phase 2 trial,” said Matthew Brewer, CEO of Havah Therapeutics. “With a susHavah Therapeutics to Present Real World Data at the RiseUp for Breast Cancer Conference
BOULDER, Colo.--(BUSINESS WIRE)--Havah Therapeutics, a clinical stage biopharmaceutical company developing innovative, proprietary hormonal implant therapies for prevention and treatment of breast cancers, today announced that the company will present real world patient data at the upcoming RiseUp for Breast Cancer Conference. The presentation will demonstrate the therapeutic potential of Havah’s novel combination implant therapy - of testosterone plus the aromatase inhibitor anastrozole - in aHavah Therapeutics Announces Formation of Clinical Advisory Board to Advance Its New Breast Cancer Treatment Approach
BOULDER, Colo.--(BUSINESS WIRE)--Havah Therapeutics, a clinical stage biopharmaceutical company developing innovative, proprietary hormonal implant therapies for prevention and treatment of breast cancers, announced the formation of their Clinical Advisory Board Chaired by Havah Therapeutics founder Stephen Birrell, MD, PhD. “The scientific and clinical guidance of this esteemed group will be invaluable as we advance our androgen targeted therapy into late-stage clinical studies for Ductal CarcQuantum Leap Healthcare Collaborative Initiates Landmark Phase 2 RECAST DCIS Platform Trial to Evaluate Alternative DCIS Treatments with Atossa Therapeutics, Havah Therapeutics, and the Menarini Group
40-site U.S. trial enrolling more than 300 patients could significantly change the way DCIS is treated and reduce possibly unnecessary surgery SAN FRANCISCO, Oct. 30, 2023 /PRNewswire/ -- Quantum Leap Healthcare Collaborative (QLHC) announces the enrollment launch for the Re-Evaluating...
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding havahtx.com
Sign Up For FreeTo access detailed company insights
HavaH Therapeutics is focused on developing innovative androgen therapies aimed at treating breast diseases, particularly hormonal refractory ER+ breast cancer and metastatic cancer. The company utilizes a unique hormonal modulation approach to provide safer and more effective treatment options for early-stage hormone receptor positive breast cance... Read More
